gw420867x has been researched along with HIV Infections in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Duval, X | 1 |
| Boyce, M; Cass, LM; Dallow, N; Hardman, TC; Jones, A; Moore, KH; Prince, WT | 1 |
| Bye, A; Drusano, GL; Kleim, JP; Moore, KH; Prince, W | 1 |
2 trial(s) available for gw420867x and HIV Infections
| Article | Year |
|---|---|
Pharmacokinetics and tolerability of GW420867X, a nonnucleoside reverse transcriptase inhibitor, following single escalating doses in healthy male volunteers.
Topics: Adolescent; Adult; Analysis of Variance; Confidence Intervals; Double-Blind Method; HIV Infections; Humans; Male; Middle Aged; Quinoxalines; Reverse Transcriptase Inhibitors | 2001 |
Rational dose selection for a nonnucleoside reverse transcriptase inhibitor through use of population pharmacokinetic modeling and Monte Carlo simulation.
Topics: Double-Blind Method; Half-Life; HIV Infections; Humans; Microbial Sensitivity Tests; Models, Biological; Monte Carlo Method; Population; Protein Binding; Quinoxalines; Reverse Transcriptase Inhibitors | 2002 |
1 other study(ies) available for gw420867x and HIV Infections
| Article | Year |
|---|---|
[The 39th ICAAC (San Francisco) and the 7th European Conference on Clinical Aspects and Treatment of HIV-infection (Lisbon). HIV infection: antiretroviral agents in the development and trial stage].
Topics: Alkynes; Animals; Anti-HIV Agents; Antiviral Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Oxazines; Quinoxalines; Reverse Transcriptase Inhibitors; Time Factors; Uracil; Viral Load | 2000 |